Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.
about
Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experienceLong-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testingMicroarray technology and its effect on breast cancer (re)classification and prediction of outcomeA multigene RT-PCR assay used to predict recurrence in early breast cancer: two presentations with contradictory resultsRespective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinomaDerivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approachFactors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.Is primary surgery of breast cancer patients consistent with German guidelines? Twelve-year trend of population-based clinical cancer registry data.Limits of predictive models using microarray data for breast cancer clinical treatment outcome.Prognostic relevance of histological grade and its components in node-negative breast cancer patients.Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy.A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?Comparison of prognostic gene expression signatures for breast cancerLeptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysisSecond-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients.Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithmsWhether drainage should be used after surgery for breast cancer? A systematic review of randomized controlled trials.Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis.Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancerA nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer.Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: a prospective observational study.Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study.Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer.Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancerATP synthase ecto-α-subunit: a novel therapeutic target for breast cancer.Breast Cancer in Countries of Limited Resources.Adherence to Treatment Guidelines in Breast Cancer Care - a Retrospective Analysis of the 'Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie'Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation.Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials.Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer.Implanting totally implantable venous access port via the internal jugular vein guided by ultrasonography is feasible and safe in patients with breast cancer.Risk of subsequent dementia diagnoses does not vary by types of adjuvant chemotherapy in older women with breast cancer.Postoperative endocrine therapy for invasive breast cancer.Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease.Severity of comorbid conditions and early-stage breast cancer therapy: linked SEER-Medicare data from 1993 to 2005.PTIP associated protein 1, PA1, is an independent prognostic factor for lymphnode negative breast cancer.
P2860
Q24792539-2CB30702-1D22-48E5-957B-C96981AC7274Q24797752-BA871EF4-D113-4096-A8BC-26080E88A8C5Q24803140-C6E8769F-9BAE-42F9-942A-1D45EDB9B54AQ24806350-7C154C4C-C04C-4FD6-B868-E6E292EB74B5Q28730529-4CE49C12-F492-4BA2-9E75-22AFC0AC4385Q28748329-05427B8D-F738-479D-BCE6-A5E30DB12FB9Q30313653-527F0C21-645C-4BC7-BD75-A550F5B8B322Q30789643-298DF3DC-C4A8-4724-8817-5A251DA6AFA3Q30992101-5A9277F7-70C4-4925-A069-0F68A95713B5Q33203070-242BCC63-E2AB-45D4-AC4B-5FB109331FB3Q33224014-625147DC-25FB-4C9F-9DAB-1F6F03ABC00CQ33352632-9759B46F-A204-43C6-B4BE-33DF658C12FEQ33362164-DD788393-B8A0-4DAD-953F-B08107AD2DFBQ33378824-9ED6596C-648F-49B8-AF3E-2139C16D1DABQ33394310-F4EAA1DA-5827-46B3-8291-20482166B29BQ33395871-F5B49EC4-CCDF-4CAB-8D17-6FFBB1350399Q33515843-B2891455-1DD9-4292-8388-70484CCA3DE3Q33651520-CAE74849-1BA2-4234-B75C-4D29FDF5E823Q33688224-0F7E437F-4484-45A8-B737-9C8D7E69EDB6Q33778433-4DBBB972-DBF6-4862-A05C-35BE6E231FB5Q33831109-1F2841F4-CC2C-42B2-8ECB-B87F6835C46AQ33852049-5AB6D4BC-CF24-4E41-91B5-F6B601A83A81Q33921197-CD0D5FA0-FB8A-43D6-A721-FE99D1B3D229Q33934494-F3FA0B34-0368-44A2-B1A7-19A5E042F3D4Q34013059-F8F06002-8831-45A3-95B5-346C89D08E1BQ34018095-88F3E069-FC2A-4349-886A-34A2BED3C29CQ34022200-1724F765-0B61-4AF9-BE7E-D17E71B9C53FQ34094912-BBBAB343-A166-44A1-9B57-36575F30A563Q34095873-19C17F07-1729-4A3F-8617-858568DC2FBAQ34096177-7F5522B0-94A7-467F-B4D3-80EB2DB0E39AQ34154192-BADD50EE-E5E2-41E9-96D2-7B6451A028E2Q34542467-7618DCDC-E254-455B-A05A-AEF2D2AE29D8Q34563697-482A7E57-A2CC-4CBD-85EB-C4B860F15D02Q34694095-4CD5779E-17EA-411B-857F-9FBA9FDB59BAQ34695723-C9C49DE5-6B6A-49BA-803F-A8F87BC3B0E8Q34815323-FA78C374-4E94-476B-9B40-7713A1CE4AF9Q34910095-19AF7AB7-4C97-4F04-8A4E-6C088D8A637BQ34977042-6CC6F77D-D77C-4ECE-B02F-DADDA1EA66E0Q35025569-BDDEECCF-111C-4036-BCCF-903EBE120B96Q35049096-7B94563C-5645-448F-8E2F-7C23F53648E3
P2860
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Meeting highlights: updated in ...... herapy of early breast cancer.
@ast
Meeting highlights: updated in ...... herapy of early breast cancer.
@en
type
label
Meeting highlights: updated in ...... herapy of early breast cancer.
@ast
Meeting highlights: updated in ...... herapy of early breast cancer.
@en
prefLabel
Meeting highlights: updated in ...... herapy of early breast cancer.
@ast
Meeting highlights: updated in ...... herapy of early breast cancer.
@en
P2093
P356
P1476
Meeting highlights: updated in ...... herapy of early breast cancer.
@en
P2093
Alan S Coates
Aron Goldhirsch
Beat Thürlimann
Hans-Jörg Senn
Richard D Gelber
William C Wood
P304
P356
10.1200/JCO.2003.04.576
P407
P577
2003-07-07T00:00:00Z